Bryan F. Cox sold $1,394 of TLSI
CHIEF SCIENTIFIC & MANUFACT. at TriSalus Life Sciences, Inc.. 314 shares at an average of $4.44, traded Oct 5, 2024, filed Dec 19, 2024.
Score components
- +15RoleOfficer
- 0Trade size$1k at market
- 0Share of holdings soldSold 0.4% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +36.9%, 3m +49.4%, 6m +49.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-029909, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 5, 2024 | SOpen-market sale Common Stock | -314 | $4.44 | $1,394 | 86,382 | Dec 19, 2024 |
Related signals
Other insiders at TriSalus Life Sciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | TriSalus Life Sciences, Inc. | Bryan F. Cox Chief of Research | $1,299 296 shares | -0% | |
| 30Weak | TriSalus Life Sciences, Inc. | Richard Marshak Chief Commercial Officer | $1,427 325 shares | -0% | |
| 30Weak | TriSalus Life Sciences, Inc. | Jennifer Stevens Chief Regulatory Officer | $1,387 316 shares | -0% | |
| 15Weak | TLSIsell TriSalus Life Sciences, Inc. | Richard Marshak Chief Commercial Officer | $1,450 543 shares | -0% | |
| 56Moderate | TriSalus Life Sciences, Inc. | Gary B. Gordon director | $25k 10,000 shares | +16% | |
| 60Notable | TriSalus Life Sciences, Inc. | David Patience Chief Financial Officer | $17k 7,100 shares | +3% | |
| 88Strong | TriSalus Life Sciences, Inc. | Michael P Stansky director | $1.5M 610,000 shares | +73% | |
| 73Notable | TriSalus Life Sciences, Inc. | Mary T Szela CEO and President | $103k 39,682 shares | +4% | |
| 69Notable | TriSalus Life Sciences, Inc. | Mats Wahlstrom director | $152k 60,000 shares | +69% | |
| 30Weak | TriSalus Life Sciences, Inc. | Bryan F. Cox Chief of Research | $13k 3,184 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.